Most parasitic worms that infect humans cannot reproduce inside the body they've invaded. They enter, mature, lay eggs that leave in the stool, and if the person is never re-exposed, the infection eventually burns out. Strongyloides stercoralis breaks that rule. Through a process called autoinfection, this small intestinal roundworm can complete its entire life cycle without ever leaving its host, allowing infections acquired in childhood or during a single tour of military service to smolder for forty, fifty, even sixty years. This article explains the biology behind that persistence, why it becomes dangerous when the immune system weakens, and the evidence supporting ivermectin as the standard treatment.
A Parasite That Can Complete Its Life Cycle Without Ever Leaving the Body
Strongyloides stercoralis is endemic in tropical and subtropical soil worldwide, including parts of the rural American South and Appalachia historically, and it remains common in Southeast Asia, sub-Saharan Africa, and Latin America. Infection begins when microscopic filariform larvae living in warm, moist soil penetrate bare skin, often through the feet. From there they travel through the bloodstream to the lungs, are coughed up and swallowed, and settle into the small intestine, where adult female worms burrow into the mucosa and begin producing eggs asexually, without ever needing a male worm. This is already unusual biology. Eggs hatch inside the gut into a non-infective larval stage (rhabditiform larvae), most of which pass out in the stool and mature in soil to become infective again, continuing the cycle in the environment. That is the ordinary route of transmission and reinfection.
The Autoinfection Cycle: How Strongyloides Achieves Near-Immortality Inside a Host
The clinically important twist is this: a portion of those rhabditiform larvae do not wait to be excreted. While still inside the intestine, or on the perianal skin as stool passes, they can transform directly into the infective filariform stage. These larvae then re-penetrate the bowel wall or the perianal skin and re-enter circulation, restarting the migratory cycle without ever leaving the body. This is the autoinfection cycle, and it is essentially unique among human helminth infections. It means a person can carry Strongyloides indefinitely from a single exposure decades earlier, with no further contact with contaminated soil.
The clinical documentation for this is strong and well known to infectious disease specialists. Studies of former World War II and Korean War prisoners of war, published in journals including the Quarterly Journal of Medicine, found active Strongyloides infection, confirmed by serology and sometimes by stool examination, in veterans more than fifty years after their presumed exposure in Southeast Asian camps, despite decades spent afterward in non-endemic countries. These findings are not an isolated curiosity; they are the reason infectious disease guidelines specifically ask about remote military service, missionary work, or residence in endemic regions, sometimes decades in the past, when strongyloidiasis is being considered.
When the Immune System Falters: Hyperinfection and Disseminated Disease
In a healthy, immunocompetent person, autoinfection typically proceeds at a low, controlled level. The classic chronic presentation is mild or even asymptomatic: intermittent abdominal discomfort, migratory skin rashes from larval movement (larva currens), and eosinophilia on routine blood work that sometimes goes unexplained for years. The danger arises when immune control is lost. Corticosteroids are the single most consistently documented trigger of hyperinfection syndrome, because they suppress the T-helper-2 (Th2) response that normally keeps larval maturation in check. Other recognized risk factors include HTLV-1 co-infection, which specifically blunts the Th2 response, solid organ transplantation, hematologic malignancy, and other immunosuppressive therapies.
When control is lost, autoinfection accelerates sharply. Larvae multiply far beyond their normal numbers and migrate widely, a state called hyperinfection syndrome. In disseminated strongyloidiasis, larvae are found in organs well outside their usual migratory path, including the brain, liver, and heart. Because migrating larvae drag intestinal bacteria through the bowel wall into the bloodstream, hyperinfection is frequently complicated by gram-negative bacteremia or meningitis, and case series in the medical literature have reported mortality rates for untreated or delayed-treatment disseminated disease ranging as high as 60 to 90 percent. This is not a theoretical risk; it is the reason major infectious disease and rheumatology societies now recommend screening at-risk patients before starting immunosuppressive treatment, a point worth returning to below.
Why Strongyloidiasis Is So Often Missed
Diagnosis is genuinely difficult, and honesty about that difficulty matters. Standard stool ova-and-parasite examination has poor sensitivity for chronic strongyloidiasis, sometimes below 50 percent on a single sample, because larval output is intermittent and low in chronic infection. Repeated stool sampling, specialized culture techniques such as the agar plate method, and serologic testing (ELISA detecting antibodies to Strongyloides antigens) each improve detection, with serology generally considered the most sensitive single test for chronic infection in someone with a plausible exposure history, though it cannot always distinguish current from past infection and can cross-react with other helminths. Eosinophilia, often treated as a reliable clue, is frequently absent in hyperinfection syndrome, which can make the most dangerous presentation the hardest to suspect. Physicians evaluating unexplained gram-negative sepsis or meningitis in a patient with any history of residence in an endemic area, however distant, are advised to consider Strongyloides specifically for this reason.
Ivermectin: A Soil Organism's Compound Against a Persistent Parasite
Ivermectin is derived from avermectins, compounds first isolated from Streptomyces avermitilis, a bacterium recovered from a soil sample in Japan in the 1970s. The discovery and development work, led by Satoshi Ōmura and William Campbell, was recognized with the 2015 Nobel Prize in Physiology or Medicine, shared with Tu Youyou for her work on artemisinin. It is a fitting reminder that some of medicine's most important tools have come not from novel synthetic chemistry but from careful observation of what was already present in the created order, waiting to be understood.
Ivermectin works by binding to glutamate-gated chloride channels found in the nerve and muscle cells of nematodes and other invertebrates. This binding causes an influx of chloride ions, paralyzing the parasite's pharyngeal and somatic muscles, which leads to its death or expulsion. These particular glutamate-gated chloride channels are not present in vertebrates, and in mammals ivermectin has very limited ability to cross the blood-brain barrier at standard doses, which together explain its wide margin of safety in humans at approved dosing.
Oral ivermectin is FDA-approved for the treatment of intestinal strongyloidiasis, and it is the treatment of choice recommended by the CDC and by infectious disease guidelines. Standard dosing for uncomplicated infection is a single oral dose of 200 micrograms per kilogram, sometimes repeated after two weeks to catch larvae that were in a less susceptible stage at the time of first treatment. A Cochrane systematic review (Henriquez-Camacho et al., published in the Cochrane Database of Systematic Reviews, 2016) comparing ivermectin to albendazole for strongyloidiasis found ivermectin achieved higher rates of parasitological cure, and it is now regarded as more effective than albendazole for this specific infection, with published cure rates for single or double-dose oral ivermectin generally in the range of roughly 83 to 95 percent across various trials and case series, depending on population and dosing schedule. For hyperinfection syndrome or disseminated disease, treatment typically requires extended daily dosing, sometimes with a rectally or subcutaneously administered veterinary formulation used off-label under close specialist supervision when oral absorption is unreliable in a critically ill patient; this is a recognized but not FDA-approved route of administration and is reserved for severe cases managed in hospital by physicians experienced with the disease.
It is worth being plain about what ivermectin is not, in this context. It is not a treatment for viral illness, and its established, evidence-backed role here is specifically antiparasitic. The strength of evidence for strongyloidiasis is genuinely high: it rests on randomized controlled trials, decades of clinical use, and an FDA-approved indication. That is a very different evidentiary footing than uses of the drug that remain investigational, and readers should not conflate the two.
Screening, Stewardship, and Personal Responsibility
Because chronic strongyloidiasis can be silent for decades and because the consequence of missing it before immunosuppression can be fatal, informed patients have good reason to raise the subject proactively with their physician rather than waiting to be asked. Anyone with a history of residence, military deployment, missionary or aid work, or birth in an endemic country, even many decades ago, is a reasonable candidate to discuss testing, particularly before starting corticosteroids for any extended period, before organ transplantation, or before biologic or other immunosuppressive therapy. This is a straightforward instance of stewardship: knowing your own or your family's health history well enough to bring it into the conversation, rather than assuming a distant exposure is irrelevant simply because it was distant. Families who have hosted returning veterans, adopted children from endemic regions, or traveled extensively for mission work carry a particular responsibility to know this history and to ask their doctor directly whether screening is appropriate. A simple blood test, discussed and consented to as part of ordinary informed medical care, can prevent a life-threatening complication that might otherwise appear only after immune suppression has already begun.
Key takeaway: Strongyloides stercoralis can persist for a lifetime through internal autoinfection, so anyone with relevant past exposure, however old, deserves an honest conversation with their physician about testing before immunosuppressive treatment, with ivermectin remaining the well-evidenced, FDA-approved treatment when infection is confirmed.